Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date
Luke Fletcher,1,2 Sunil K Joshi,1–3 Elie Traer1,2 1Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR 97239, USA; 2Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA; 3School of Medicine, Oregon He...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-01-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/profile-of-quizartinib-for-the-treatment-of-adult-patients-with-relaps-peer-reviewed-article-CMAR |
id |
doaj-6532a652d3654a0d9c09bd98ef924e71 |
---|---|
record_format |
Article |
spelling |
doaj-6532a652d3654a0d9c09bd98ef924e712020-11-25T02:34:05ZengDove Medical PressCancer Management and Research1179-13222020-01-01Volume 1215116350941Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to DateFletcher LJoshi SKTraer ELuke Fletcher,1,2 Sunil K Joshi,1–3 Elie Traer1,2 1Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR 97239, USA; 2Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA; 3School of Medicine, Oregon Health & Science University, Portland, OR 97239, USACorrespondence: Elie TraerOregon Health & Science University, 3181 SW Sam Jackson Park Road, Mail Code: KR-HEM, Portland, OR 97239, USATel +1 503 494 3553Fax +1 503 494 3465Email traere@ohsu.eduAbstract: Acute myeloid leukemia (AML) is a clonal hematologic neoplasm characterized by rapid, uncontrolled cell growth of immature myeloid cells (blasts). There are numerous genetic abnormalities in AML, many of which are prognostic, but an increasing number are targets for drug therapy. One of the most common genetic abnormalities in AML are activating mutations in the FMS-like tyrosine kinase 3 receptor (FLT3). As a receptor tyrosine kinase, FLT3 was the first targetable genetic abnormality in AML. The first generation of FLT3 inhibitors were broad-spectrum kinase inhibitors that inhibited FLT3 among other proteins. Although clinically active, first-generation FLT3 inhibitors had limited success as single agents. This led to the development of a second generation of more selective FLT3 inhibitors. This review focuses on quizartinib, a potent second-generation FLT3 inhibitor. We discuss the clinical trial development, mechanisms of resistance, and the recent FDA decision to deny approval for quizartinib as a single agent in relapsed/refractory AML.Keywords: FLT3, quizartinib, AML, resistance, clinical trials, QuANTUMhttps://www.dovepress.com/profile-of-quizartinib-for-the-treatment-of-adult-patients-with-relaps-peer-reviewed-article-CMARflt3quizartinibamlresistanceclinical trialsquantum |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Fletcher L Joshi SK Traer E |
spellingShingle |
Fletcher L Joshi SK Traer E Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date Cancer Management and Research flt3 quizartinib aml resistance clinical trials quantum |
author_facet |
Fletcher L Joshi SK Traer E |
author_sort |
Fletcher L |
title |
Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date |
title_short |
Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date |
title_full |
Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date |
title_fullStr |
Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date |
title_full_unstemmed |
Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date |
title_sort |
profile of quizartinib for the treatment of adult patients with relapsed/refractory flt3-itd-positive acute myeloid leukemia: evidence to date |
publisher |
Dove Medical Press |
series |
Cancer Management and Research |
issn |
1179-1322 |
publishDate |
2020-01-01 |
description |
Luke Fletcher,1,2 Sunil K Joshi,1–3 Elie Traer1,2 1Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR 97239, USA; 2Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA; 3School of Medicine, Oregon Health & Science University, Portland, OR 97239, USACorrespondence: Elie TraerOregon Health & Science University, 3181 SW Sam Jackson Park Road, Mail Code: KR-HEM, Portland, OR 97239, USATel +1 503 494 3553Fax +1 503 494 3465Email traere@ohsu.eduAbstract: Acute myeloid leukemia (AML) is a clonal hematologic neoplasm characterized by rapid, uncontrolled cell growth of immature myeloid cells (blasts). There are numerous genetic abnormalities in AML, many of which are prognostic, but an increasing number are targets for drug therapy. One of the most common genetic abnormalities in AML are activating mutations in the FMS-like tyrosine kinase 3 receptor (FLT3). As a receptor tyrosine kinase, FLT3 was the first targetable genetic abnormality in AML. The first generation of FLT3 inhibitors were broad-spectrum kinase inhibitors that inhibited FLT3 among other proteins. Although clinically active, first-generation FLT3 inhibitors had limited success as single agents. This led to the development of a second generation of more selective FLT3 inhibitors. This review focuses on quizartinib, a potent second-generation FLT3 inhibitor. We discuss the clinical trial development, mechanisms of resistance, and the recent FDA decision to deny approval for quizartinib as a single agent in relapsed/refractory AML.Keywords: FLT3, quizartinib, AML, resistance, clinical trials, QuANTUM |
topic |
flt3 quizartinib aml resistance clinical trials quantum |
url |
https://www.dovepress.com/profile-of-quizartinib-for-the-treatment-of-adult-patients-with-relaps-peer-reviewed-article-CMAR |
work_keys_str_mv |
AT fletcherl profileofquizartinibforthetreatmentofadultpatientswithrelapsedrefractoryflt3itdpositiveacutemyeloidleukemiaevidencetodate AT joshisk profileofquizartinibforthetreatmentofadultpatientswithrelapsedrefractoryflt3itdpositiveacutemyeloidleukemiaevidencetodate AT traere profileofquizartinibforthetreatmentofadultpatientswithrelapsedrefractoryflt3itdpositiveacutemyeloidleukemiaevidencetodate |
_version_ |
1724810264375721984 |